Icosapent ethyl or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA). It is used as an adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL) and to reduce the risk of cardiovascular events in certain patients with elevated triglycerides. FDA approved on July 26, 2012.
作为最大耐受他汀类药物治疗的辅助手段,以降低甘油三酯(TG)水平升高(≥150mg/dL)、已确定的心血管疾病或糖尿病以及2个或更多心血管疾病风险因素的成年患者需要住院治疗的心肌梗死、中风、冠状动脉血运重建和不稳定心绞痛的风险。
Iwate Medical University, Morioka, Iwate, Japan
Yamaguchi University Hospital, Ube, Yamaguchi, Japan
Ootemachi Hospital, Kitakyushu, Fukuoka, Japan
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.